Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in
allogeneic cellular medicines for inflammatory diseases, will host
a webinar focused on the current treatment landscape and unmet
medical need for patients with chronic low back pain (CLBP) due to
degenerative disc disease, a condition associated with local
inflammation in the disc. The webinar will feature presentations
from Key Opinion Leaders (KOLs) Douglas P. Beall, MD, FIPP, FSIR,
DAAPM (Clinical Radiology Oklahoma) and Hyun W. Bae, MD
(Spine-Center at Cedars-Sinai Medical Center).
Mesoblast’s Chief Executive Silviu Itescu will provide an
overview of the three-year outcomes from the completed 404 patient
randomized controlled Phase 3 trial of rexlemestrocel-L in patients
with CLBP due to degenerative disc disease and regulatory pathway
to market.
The webinar will begin at 6.00pm EDT, Thursday, June 16; 8.00am
AEST, Friday, June 17, 2022. Registration will be required in
advance for the webcast, to access click here or use the following
link:
https://lifesci.rampard.com/WebcastingAppv5/Events/eventsDispatcher.jsp?Y2lk=MTg2OA==
The archived webcast will be available on the Investor page of
the Company’s website: www.mesoblast.com
Speaker Biographies
Douglas P. Beall, MD, FIPP, FSIR, DAAPM Douglas
P. Beall, MD, FIPP, FSIR, DAAPM attended medical school at
Georgetown University School of Medicine in Washington, DC, and
completed his residency at The Johns Hopkins Hospital in Baltimore,
Maryland. Following residency, he was Chief of Interventional
Services at Sheppard Air Force Base in Wichita Falls, Texas. He
then completed a fellowship in Musculoskeletal Radiology at Mayo
Clinic in Rochester, Minnesota, where he was trained in
interventional spine techniques before returning to the US Air
Force as Division Chief of Musculoskeletal Radiology. Following his
service as a Major in the US Air Force Dr. Beall was chief of
Musculoskeletal Radiology and Fellowship Director at the University
of Oklahoma prior to entering private practice as the Chief of
Services. In addition to his expertise in musculoskeletal imaging
and interventional spine care, Dr. Beall is actively involved in
teaching and research. He is board-certified in Diagnostic
Radiology, has an added fellowship in Musculoskeletal Radiology, is
a Diplomate of the American Academy of Pain Management and is a
Fellow of the Society of Interventional Radiology and
Interventional Pain Practice and board certified by the World
Institute of Pain. He is currently in private practice focused on
interventional pain management and orthopedic imaging.
Dr. Beall has published more than 250 articles in peer-reviewed
journals, authored 6 textbooks and 75 textbook chapters, given more
than 1000 invited lectures and scientific presentations and has
participated in 55 clinical research trials. He is currently the
Chief of Services for Comprehensive Specialty Care in Oklahoma City
as well as the Division Head of Interventional Spine Care and
Director of Pain Management Fellowship Programs at the Spine
Fracture Institute and the Comprehensive Care Surgical Center.
Hyun W. Bae, MDHyun W. Bae, MD is an orthopedic
and spine fellowship trained board-certified orthopedic surgeon. Dr
Bae joined the Spine-Center at Cedars-Sinai Medical Center in 2010.
He is currently Professor of Surgery in the Department of
Orthopedic Surgery Cedars-Sinai Medical Center, Director of
Education and Fellowship program.
Dr. Bae began his medical studies at Columbia University School
of Engineering and Applied Sciences where he graduated with a
degree in biomechanics. He then went on to earn his medical degree,
cum laude, at Yale University School of Medicine. Dr. Bae completed
his surgical internship at North Shore University Hospital and his
orthopedic surgical residency at the Hospital for Special Surgery
in New York. He completed his spine fellowship at Case Western
Hospital in Cleveland under the mentorship of late Henry H.
Bohlman, MD.
During 1993-1994 he performed research in Molecular and Cell
Biology, NIH Howard Hughes Research Fellow Bethesda, MD. It was
during that time, he caught the passion for musculoskeletal tissue
engineering while working with scientists Guilak F, Setton LA,
Soslowsky LJ, as an undergraduate in Dr. Van Mow’s cartilage
research laboratory.
About Mesoblast Mesoblast is a world leader in
developing allogeneic (off-the-shelf) cellular medicines for the
treatment of severe and life-threatening inflammatory conditions.
The Company has leveraged its proprietary mesenchymal lineage cell
therapy technology platform to establish a broad portfolio of
late-stage product candidates which respond to severe inflammation
by releasing anti-inflammatory factors that counter and modulate
multiple effector arms of the immune system, resulting in
significant reduction of the damaging inflammatory process.
Mesoblast has a strong and extensive global intellectual
property portfolio with protection extending through to at least
2041 in all major markets. The Company’s proprietary manufacturing
processes yield industrial-scale, cryopreserved, off-the-shelf,
cellular medicines. These cell therapies, with defined
pharmaceutical release criteria, are planned to be readily
available to patients worldwide.
Mesoblast is developing product candidates for distinct
indications based on its remestemcel-L and rexlemestrocel-L
allogeneic stromal cell technology platforms. Remestemcel-L is
being developed for inflammatory diseases in children and adults
including steroid refractory acute graft versus host disease,
biologic-resistant inflammatory bowel disease, and acute
respiratory distress syndrome. Rexlemestrocel-L is in development
for advanced chronic heart failure and chronic low back pain. Two
products have been commercialized in Japan and Europe by
Mesoblast’s licensees, and the Company has established commercial
partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United States and
Singapore and is listed on the Australian Securities Exchange (MSB)
and on the Nasdaq (MESO). For more information, please see
www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter:
@Mesoblast
Forward-Looking StatementsThis press release
includes forward-looking statements that relate to future events or
our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to differ
materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking
statements. We make such forward-looking statements pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995 and other federal securities laws. Forward-looking
statements should not be read as a guarantee of future performance
or results, and actual results may differ from the results
anticipated in these forward-looking statements, and the
differences may be material and adverse. Forward-looking statements
include, but are not limited to, statements about: the initiation,
timing, progress and results of Mesoblast’s preclinical and
clinical studies, and Mesoblast’s research and development
programs; Mesoblast’s ability to advance product candidates into,
enroll and successfully complete, clinical studies, including
multi-national clinical trials; Mesoblast’s ability to advance its
manufacturing capabilities; the timing or likelihood of regulatory
filings and approvals (including BLA resubmission), manufacturing
activities and product marketing activities, if any; the
commercialization of Mesoblast’s product candidates, if approved;
regulatory or public perceptions and market acceptance surrounding
the use of stem-cell based therapies; the potential for Mesoblast’s
product candidates, if any are approved, to be withdrawn from the
market due to patient adverse events or deaths; the potential
benefits of strategic collaboration agreements and Mesoblast’s
ability to enter into and maintain established strategic
collaborations; Mesoblast’s ability to establish and maintain
intellectual property on its product candidates and Mesoblast’s
ability to successfully defend these in cases of alleged
infringement; the scope of protection Mesoblast is able to
establish and maintain for intellectual property rights covering
its product candidates and technology; estimates of Mesoblast’s
expenses, future revenues, capital requirements and its needs for
additional financing; Mesoblast’s financial performance;
developments relating to Mesoblast’s competitors and industry; and
the pricing and reimbursement of Mesoblast’s product candidates, if
approved. You should read this press release together with our risk
factors, in our most recently filed reports with the SEC or on our
website. Uncertainties and risks that may cause Mesoblast’s actual
results, performance or achievements to be materially different
from those which may be expressed or implied by such statements,
and accordingly, you should not place undue reliance on these
forward-looking statements. We do not undertake any obligations to
publicly update or revise any forward-looking statements, whether
as a result of new information, future developments or
otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
Corporate Communications / Investors |
Media |
Paul Hughes |
Sumit Media |
T: +61 3 9639 6036 |
Grant Titmus |
E: investors@mesoblast.com |
T: +61 419 388 161 |
|
E: grant@sumitmedia.com.au |
|
|
|
Rubenstein |
|
Tali Mackay |
|
E: tmackay@rubenstein.com |
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jul 2023 to Jul 2024